FATTY ACID OXIDATION DISORDERS

Carnitine Uptake Defect (CUD)

Background

Carnitine uptake defect (CUD) is a condition that prevents the body from using fats for energy, particularly during periods without food (fasting). Carnitine, a natural substance acquired mostly through diet, is used by cells to process fats and produce energy. In people with CUD, proteins called carnitine transporters do not work properly. These proteins normally bring carnitine into cells and prevent the escape of carnitine from the body in urine. CUD is estimated to occur in less than 1 of 100 000 live births. However it has been reported to have an incidence rate of 1:40 000 live births in Japan.

Clinical

Typically, initial signs and symptoms of this disorder occur during infancy or early childhood and often include changes in brain tissue (encephalopathy) resulting in functional abnormalities; an enlarged, poorly pumping heart (cardiomyopathy); confusion; vomiting; muscle weakness; and low blood sugar (hypoglycemia). Serious complications such as heart failure, liver problems, coma, and sudden unexpected death are also a risk. Severe illness due to CUD can be triggered by periods of fasting or illnesses such as viral infections, particularly when eating is reduced.

This condition is sometimes mistaken for Reye syndrome, a severe disorder that develops in children while they appear to be recovering from viral infections such as chicken pox or flu.

Testing

Newborn screening using tandem mass spectrometry of a dried blood spot identifies low level of free carnitine (C0). (C0+C2+C3+C16+C18:1+C18)/Cit is also found as informative ratio. Plasma and urine carnitine analysis will reveal decreased free and total carnitine (C0) in plasma and overexcretion of carnitine in urine. The newborn’s mother should be investigated, as well, because several cases of maternal CUD have been identified following an abnormal newborn screening result in their offspring. Transporter assays and OCTN2 gene sequencing establish the diagnosis.

Treatment

Treating CUD patients with oral L-carnitine supplementation is followed by a slow increase of plasma carnitine levels. If the infants’ levels reflect maternal primary carnitine deficiency, the rise in plasma levels is fast and this should prompt the work-up towards the diagnosis of maternal primary carnitine deficiency. CUD patients should also avoid fasting and sometimes low-fat, high carbonhydrate diet is used in addition to L-carnitine. Guidelines for the management of carnitine deficiency and other fatty acid mitochondrial disorders have been established.

Because the diagnosis and therapy of CUD is complex, the pediatrician is advised to manage the patient in close collaboration with a consulting pediatric metabolic disease specialist. It is recommended that parents travel with a letter of treatment guidelines from the patient’s physician.

Inheritance

This disorder follows an autosomal recessive inheritance pattern. With recessive disorders affected patients usually have two copies of a disease gene (or mutation) in order to show symptoms. People with only one copy of the disease gene (called carriers) generally do not show signs or symptoms of the condition but can pass the disease gene to their children. When both parents are carriers of the disease gene for a particular disorder, there is a 25% chance with each pregnancy that they will have a child affected with the disorder.

WORKFLOW

Instruments for Carnitine Uptake Defect (CUD)

QSight® MD Screening Systems

QSight® MD Screening Systems

The QSight® MD mass spectrometry screening systems are designed for routine high throughput quantitation. They offer expanded screening for a variety of inborn errors of metabolism with a wide analyte panel, and access to Tier 2 chromatography (QSight® 225 MD UHPLC only).
WORKFLOW

Compatible kits for Carnitine Uptake Defect (CUD)

NeoBase™ 2 Non-derivatized MSMS kit

First SMA baby identified with our screening solutions in Australia
Newborn
26 Apr 2021

First SMA baby identified with our screening solutions in Australia

A newborn baby has been identified as having SMA (spinal muscular atrophy) in Westmead Children’s Hospital in Australia, using a 4-plex SMA, SCID and XLA laboratory developed test
Multiplex Real-time PCR Newborn Screening Assay to Simultaneously Identify Spinal Muscular Atrophy and Severe Combined Immunodeficiency
Newborn
26 May 2021

Multiplex Real-time PCR Newborn Screening Assay to Simultaneously Identify Spinal Muscular Atrophy and Severe Combined Immunodeficiency

Professor Mei Baker discusses Identifying Spinal Muscular Atrophy and Severe Combined Immunodeficiency using Real-time PCR newborn screening
Expanded newborn screening – An interview with Dr. Marianna Messina
Newborn
22 Apr 2021

Expanded newborn screening – An interview with Dr. Marianna Messina

Dr. Marianna Messina discusses her experiences introducing expanded screening to her laboratory in Italy.

PerkinElmer does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations please consult your local health care professionals.

 

GET IN TOUCH

Take the next step

Speak with a sales person

Talk to one of our product experts about the right solutions for you.

Contact us today

View more resources

Explore our articles and resources section for the latest information

Learn More

Read the lastest news

Sign up for our newsletter to find out about the latest news from PerkinElmer and the industry

Sign up
shutterstock_1689772501 1

Find out the latest news

Join our email list for industry news, webinars and the latest information about PerkinElmer’s solutions for Reproductive Health